Point72 Asset Management
OVID icon

Point72 Asset Management’s Ovid Therapeutics OVID Stock Holding History

Point72 Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.23M Buy
1,945,727
+625,117
+47% +$1.61M 0.01% 1724
2026
Q1 		$2.93M Sell
1,320,610
-2,230,519
-63% -$3.99M ﹤0.01% 2059
2025
Q4 		$5.79M Buy
+3,551,129
New +$5.47M 0.01% 1730

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point72 Asset Management's OVID Position: Q2 2026 in Review

Point72 Asset Management increased its Ovid Therapeutics (OVID) stake by 47% in Q2 2026, buying an estimated $1.61M and bringing the position to 1,945,727 shares worth $5.23M. The position accounts for 0.01% of the portfolio, ranked #1724.

Point72 Asset Management first reported a position in OVID in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.79M in Q4 2025. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Point72 Asset Management held 1,945,727 shares of Ovid Therapeutics worth $5.23M as of Q2 2026.
  • Point72 Asset Management bought 625,117 Ovid Therapeutics shares in Q2 2026, an estimated $1.61M.
  • Ovid Therapeutics made up 0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1724 holding.
  • Point72 Asset Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Point72 Asset Management's Ovid Therapeutics position peaked at $5.79M in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.